Smarter News Now
  • About Us
  • Privacy Policy
  • Terms & Conditions
  • Contact Us
  • Email Whitelisting
No Result
View All Result
  • Top News
  • Economy News
  • Forex News
  • Investing News
  • Stock News
  • Politics News
  • Editor’s Pick
  • Top News
  • Economy News
  • Forex News
  • Investing News
  • Stock News
  • Politics News
  • Editor’s Pick
No Result
View All Result
Smarter News Now
No Result
View All Result
Home Top News

Trump administration awards contract to make COVID-19 drugs in U.S.

by
May 19, 2020
in Top News
0
Trump administration awards contract to make COVID-19 drugs in U.S.
0
SHARES
12
VIEWS
Share on FacebookShare on Twitter
imageEconomy5 hours ago (May 19, 2020 11:05AM ET)

(C) Reuters. U.S. President Trump hosts coronavirus response event with restaurant executives and industry leaders at the White House in Washington

By Michael Erman and Ankur Banerjee

(Reuters) – U.S. President Donald Trump’s administration awarded a contract worth up to $812 million for a new U.S. company to manufacture drugs and drug ingredients to fight COVID-19 on American soil, aiming to end dependence on other countries.

The administration has been looking to build up the ability to produce drugs and their raw materials in the United States after the global pandemic exposed the industry’s dependence on China and India for its supply chain.

“For far too long, we’ve relied on foreign manufacturing and supply chains for our most important medicines and active pharmaceutical ingredients while placing America’s health, safety, and national security at grave risk,” Peter Navarro, director of the White House Office of Trade and Manufacturing Policy, said in a statement.

The U.S Department of Health and Human Services said on Tuesday that it had awarded a 4-year, $354 million contract to privately-held Phlow Corp to make COVID-19 drugs, other essential drugs and their ingredients. The contract can be extended for up to $812 million over 10 years.

Phlow, which was incorporated in January, said the contract will help it contribute to a national stockpile of active pharmaceutical ingredients for essential medicines.

It said it had already started making pharmaceutical ingredients and finished dosage forms for over a dozen essential medicines to treat hospitalized patients with COVID-19-related illnesses. It has delivered over 1.6 million doses of five essential generic medicines used to treat COVID-19 patients to the U.S. Strategic National Stockpile.

Many of these medicines are in shortage and have previously been imported. India and China account for a vast majority of active pharmaceutical ingredients used to make drugs in the United States.

Phlow has partnered with other groups including Civica Rx, Ampac Fine Chemicals and the Medicines for All Institute to manufacture the medicines.

All pharmaceutical products by Phlow will be made in the United States, according to the company’s website. The company said it is working to build advanced manufacturing capability in Virginia, as well as sterile injectables manufacturing facilities.

Trump administration awards contract to make COVID-19 drugs in U.S.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

ShareTweetPin

Related Posts

bose corp
Top News

Bose Stock: Advantages of Investing in the Modern Audio Business

July 13, 2021
HEB store
Top News

What Is the HEB Grocery Stock Price & Value?

July 7, 2021
OnlyFans logo
Top News

OnlyFans Stock: What Is the Point to Invest in Popular Adults Only Service?

July 6, 2021
what is IV crush
Top News

IV Crush: Why You Should Be Aware of a Volatility Crush

June 23, 2021
cryptocurrencies
Top News

What are cryptocurrencies or how to earn 6000% profit

June 2, 2021
swiss-bank
Top News

Where do Swiss Banks Advise To Invest

June 1, 2021
Next Post
S&P 500, Dow edge lower after mixed retail earnings

S&P 500, Dow edge lower after mixed retail earnings

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Email Address *
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
 

Recommended

ICC opens probe of Duterte’s drug war

September 16, 2021
Germany stocks lower at close of trade; DAX down 3.43%

Germany stocks lower at close of trade; DAX down 3.43%

June 24, 2020
Philippines can secure up to 25 million doses of Moderna, Arcturus vaccines — ambassador

Philippines can secure up to 25 million doses of Moderna, Arcturus vaccines — ambassador

December 18, 2020

Facebook became Meta – Are we all about to jump in to the Metaverse?

April 25, 2022

Higher shop prices loom says boss of Unilever

October 22, 2021
Top House Republican McCarthy confirms deal reached on small business loan bill

Top House Republican McCarthy confirms deal reached on small business loan bill

April 21, 2020
  • About Us
  • Privacy Policy
  • Terms & Conditions
  • Contact Us
  • Email Whitelisting

Copyright © 2022 SmarterNewsNow.
All Rights Reserved.

Disclaimer: SmarterNewsNow.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.
The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

No Result
View All Result
  • About Us
  • Contact Us
  • Email Whitelisting
  • Home
  • Privacy Policy
  • Terms & Conditions
  • Thank You

Copyright © 2020 SmarterNewsNow. All Rights Reserved.